This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements
by Zacks Equity Research
Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.
Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
by Zacks Equity Research
Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) reachead $65.80 at the closing of the latest trading day, reflecting a +1.83% change compared to its last close.
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
by Sundeep Ganoria
VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) reachead $65.85 at the closing of the latest trading day, reflecting a +0.72% change compared to its last close.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
by Zacks Equity Research
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.45, representing a -0.3% change from its previous close.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $64.96, denoting a +1.33% change from the preceding trading day.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
by Zacks Equity Research
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $64.11, marking a -0.9% move from the previous day.
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug
by Zacks Equity Research
FDA's breakthrough therapy designation for SGMT's denifanstat for MASH with moderate-to-advanced liver fibrosis is based on phase IIb FASCINATE-2 study data.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $61.68, marking a -1.03% move from the previous day.
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $63.13, representing a +1.94% change from its previous close.
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
by Zacks Equity Research
Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
by Zacks Equity Research
Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms and improved physical function.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) closed at $67.10 in the latest trading session, marking a +0.55% move from the prior day.
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
by Kinjel Shah
Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
by Zacks Equity Research
NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX
by Andrew Rocco
The 200-day moving average can provide some of the best long-term entry points. MicroStrategy, Coinbase, and Viking Therapeutics offer high reward-to-risk as they retreat to an important technical level.
Viking Therapeutics, Inc. (VKTX) Laps the Stock Market: Here's Why
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $54.78, signifying a +1.2% move from its prior day's close.
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) reachead $58.10 at the closing of the latest trading day, reflecting a -0.5% change compared to its last close.
Viking Surges 342% in the Past Year: How Should You Play the Stock?
by Sundeep Ganoria
VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.